title: [Study on economic burden caused by antiretroviral treatment for people living with HIV/AIDS and influencing factors in Nanjing].
abstract: OBJECTIVE
  To understand the economic burden caused by antiretroviral treatment for people living with HIV/AIDS and influencing factors in Nanjing.
  
  
  METHODS
  People living with HIV/AIDS were divided into two groups, HIV infected patients and AIDS patients. The data about their direct medical expenditure, direct non-medical expenditure and indirect economic loss in the past year were collected. Univariate and multivariate analysis were conducted to identify the potential influencing factors.
  
  
  RESULTS
  The median of direct medical expenditure and total costs for 133 HIV infected patients were 1,200 yuan RMB and 1,972 yuan RMB respectively. The median of direct medical expenditure and total costs for 145 AIDS patients were 1 060 yuan RMB and 2 826 yuan RMB respectively. The differences in direct medical expenditure and total costs between HIV infected patients and AIDS patients showed no statistical significance. The results from univariate analysis indicated that the sample source influenced total costs significantly. Multivariate analysis showed that onset time and CD level were negatively correlated with direct medical expenditure. The patients infected through heterosexual contact had more direct medical expenditure than those infected through homosexual contact. The patients receiving HIV test in hospitals had more direct medical expenditure than those receiving volunteer counseling and testing.
  
  
  CONCLUSIONS
  Further efforts should be made to expand HIV testing and treatment coverage in order to detect HIV infections as early as possible. Early antiretroviral treatment should be given to HIV infected patients to maintain their immunity and reduce their medical expenditure.
authors.affiliation: National Center for ADIS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: Xiayan
authors.initials: X
authors.lastname: Zhang
authors.affiliation: National Center for ADIS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: Meng
authors.initials: M
authors.lastname: Li
authors.affiliation: National Center for ADIS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: Yibing
authors.initials: Y
authors.lastname: Feng
authors.affiliation: National Center for ADIS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Bu
authors.affiliation: Jiangsu Provincial Center for Disease Control and Prevention.
authors.forename: Gengfeng
authors.initials: G
authors.lastname: Fu
authors.affiliation: Jiangsu Provincial Center for Disease Control and Prevention.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Liu
authors.affiliation: Jiangsu Provincial Center for Disease Control and Prevention.
authors.forename: Yuheng
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Jiangsu Provincial Center for Disease Control and Prevention.
authors.forename: Lingen
authors.initials: L
authors.lastname: Shi
authors.affiliation: The Second Hospital of Nanjing.
authors.forename: Chunqin
authors.initials: C
authors.lastname: Bai
authors.affiliation: The Second Hospital of Nanjing.
authors.forename: Hongxia
authors.initials: H
authors.lastname: Wei
authors.affiliation: Jiangsu Provincial Center for Disease Control and Prevention; Email: huanxip@vip.sina.com.
authors.forename: Xiping
authors.initials: X
authors.lastname: Huan
authors.affiliation: National Center for ADIS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Email: wanglu64@163.com.
authors.forename: Lu
authors.initials: L
authors.lastname: Wang
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000191:economics*; D044966:Anti-Retroviral Agents / Q000191:economics* / Q000627:therapeutic use; D002681:China; D017281:Cost of Illness; D003376:Counseling; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics*; D005102:Health Expenditures / Q000706:statistics & numerical data*; D020010:Heterosexuality; D006801:Humans; D008403:Mass Screening; D035141:Voluntary Programs
chemical_list: D044966:Anti-Retroviral Agents